Flagship Pioneering-backed Sail Biomedicines has laid off 12 employees following a review of the company’s organizational ...

Biology — the science of life, living things and the processes that keep us all running — links up in essential ways with ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...

Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

Gennova Biopharmaceuticals Ltd. on Tuesday announced that it is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI), a subsidiary of Emcure Pharmaceuticals Ltd. for the ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin ...

When the transatlantic startup AIRNA launched in 2023, it was already years behind other companies that were trying to bring ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...